The labex gathers 16 teams (7 rated A+, 8 rated A by the AERES) belonging to 5 research units. They have an excellent track record in terms of publications (60 publications with IF>10 since 2006), technology transfer and translational immunology.
- 5 teams UMR892, Nantes
- 1 team UMR892, Angers
- U917, Rennes
- U1102, Nantes
Immuno-transplantation and autoimmunity
- 5 teams UMR1064, Nantes
- EA2216, INSERM ESPRI, ERI29, Brest
Oncogenesis and nuclear oncology
- 2 teams UMR892, Nantes
Seven teams from the CRCNA (4 rated A+, 3 rated A) will contribute to the Labex IGO : team 1 (E. Scotet) (A+), team 3 (N. Labarriere) (A+), team 6 (Y. Jacques) (A), team 9 (F. Vallette) (A), team 13 (F. Kraeber-Bodéré et M. Chérel) (A+), team 15 (Y. Delneste) (A+) and team 16 (B. Dreno) (A).
These teams have contributed to our improved understanding of the immunobiology of several human immune subsets and molecules (gd T cells, tumor-specific ab T cells, hemopoietic cytokines, innate receptors and myeloid cells), have been actively involved in the analysis of their contribution to various physiopathological processes (immune control of infections and tumors, autoimmunity) and have implemented several immunotherapeutic approaches in humans using gd T cell agonists, tumor vaccines, passive transfer of T cells and immunocytokines, thanks to tight collaborations established with clinicians and private partners. Highly cited publications and innovative diagnostic and therapeutic approaches based on immunological targeting of radionuclides attest to the recognized expertise of tumor cell survival pathways involving Bcl family members and nuclear oncology,which will be brought to the network by two CRCNA teams.
Several teams (2 rated A+, 3 rated A) from the CRTI will contribute to the Labex IGO : team 1 (M. C. Cuturi/R. Josien) (A), team 2 (I. Anegon) (A+), team 3 (B. Vanhove) (A+), team 4 (S. Brouard/D. Laplaud) (A) and team 5 (B. Charreau/F. Fakhouri) (A). These teams made major observations in : DC subsets and tolerogenic DCs in animal models and Patients and identification of new regulators of immune responses, identification of CD8+ Tregs in rats and humans and analysis of their mechanism of action including new immunoregulatory molecules, generation of tolerogenic DCs and immune models of transgenic and KO rats, generation of new costimulation blocking agents, identification of MDSCs in transplantation and the use of humanized mice and primates in immune settings, identification of Bregs and new immunoregulatory molecules in tolerant patients and animal models, analysis of T CD8+ effector cells in transplanted patients and analysis of immune responses in multiple sclerosis, biology of endothelial cells and immune responses.
CRTI teams will also contribute to IGO with platforms and equipments.
UMR 917 has been developing two main research axis focused on the biology of B‐cell lymphomas: the study of normal and malignant B‐cell differentiation and the study of normal and malignant B‐cell niches. It has significantly contributed to the characterization of human B‐cell subsets and identification of the key roles of infiltrating stromal cells, TFH and macrophages in lymphoma pathogenesis. The team has also developed translational projects in partnership with big pharmas : Evaluation of anti‐lymphoma drugs with a specific focus on pro-apoptotic molecules and immunomodulatory antibodies (anti‐CD137) ; Identification and characterization of lymphoma blood biomarkers using proteomic and transcriptomic approaches ; Clinical applications of mesenchymal stromal cells (MSC). Partner 3 is actively engaged in two FP7 programs on the clinical use of MSC (CASCADE & REBORNE) and in an ITN network (STROMA).
The research of UMR 1102 concentrates particularly on the study of Cancer Testis Antigens (CTA) that are expressed in human germ cells and cancer cells but not in normal cells in adult somatic tissues. One antigen in particular, called NY-ESO-1, characterized by its remarkable spontaneous immunogenicity, is at the heart of the pre-clinical and clinical research programs of the Unit. A second area of research explores the impact of immunoregulation in cancer, focusing in particular on FOXP3 Treg, a population that plays major roles in regulating T cell homeostasis and controlling exuberant immune responses, but that also limits the development of anti-tumor immunity. The research program of the Unit is conducted in collaboration with the Ludwig Institute for Cancer Research and the Cancer Research Institute in the frame of a global program: the Cancer Vaccine Collaborative. The long-term objective of the Unit is to participate to the transformation of therapeutic approaches in oncology through an increasing incorporation of immunotherapy and to play a tangible role in the development of human anti-cancer vaccines.
EA2216 will work on the study of normal and pathological B lymphocytes with applications to autoimmune diseases (rheumatoid arthritis, lupus and Sjögren’s syndrome), kidney graft rejection and lymphoproliferative B‐cell disorders. The team research extends from the most upstream approaches (CD5 B cells and epigenetic, regulatory B lymphocytes, the genetic control of BAFF, CD22 on B cells and its relationships with IVIg to downstream ones (multi-center trials, patents in B‐cell immunotherapy, STREP. Since 2006, partner 5 has published 188 manuscripts in refereed international journals (56 with IF>6, 4 with IF>10), initiated 4 PHRC projects and performed 9 phase II and 10 phase III clinical trials.
Doctorants and post-doctorants financed by LABEX IGO
- part. 5 firstname.lastname@example.org
- part. 5 email@example.com
- part. 3 firstname.lastname@example.org
- part. 2 email@example.com
- part. 1 firstname.lastname@example.org
- part. 1 email@example.com
- part. 1 Ulrich.Jarry@univ-nantes.fr
- part. 2 firstname.lastname@example.org
- part. 2 email@example.com
- part. 1 firstname.lastname@example.org
- part. 1 email@example.com
- part. 1 firstname.lastname@example.org
- part. 5 L. Le Lann – pers@univ-brest.Fr
Doctorants and post-doctorants – UNIT EA2216
Doctorants and post-doctorants – UNIT 917
Doctorants and post-doctorants – UNIT 1064
Doctorants and post-doctorants – UNIT 892